tiprankstipranks
Trending News
More News >
Collplant Holdings (CLGN)
NASDAQ:CLGN
Advertisement

Collplant Holdings (CLGN) AI Stock Analysis

Compare
175 Followers

Top Page

CLGN

Collplant Holdings

(NASDAQ:CLGN)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 4o)
Rating:40Underperform
Price Target:
$2.50
▲(9.65% Upside)
Collplant Holdings has a low overall stock score due to significant financial challenges, including declining revenue and negative cash flow. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. These factors collectively suggest a high-risk investment without clear positive catalysts.
Positive Factors
Innovative Product Development
The successful development of Collink.3D as a next-generation, animal-free extracellular matrix enhances CollPlant's position in tissue engineering, supporting long-term growth in regenerative medicine.
Strategic Partnerships
Collaboration with Mayo Clinic on a 3D bioprinted skin model underscores CollPlant's ability to form strategic partnerships, expanding its technological reach and market applications in regenerative medicine.
Market Expansion
Expanding the distribution network for VergenixSTR in Europe enhances CollPlant's market presence and potential revenue streams, supporting long-term growth in the regenerative medicine market.
Negative Factors
Revenue Decline
A significant revenue decline indicates challenges in product sales and market penetration, potentially impacting CollPlant's financial stability and ability to fund future growth initiatives.
Negative Cash Flow
Persistent negative cash flow reflects operational inefficiencies and may limit CollPlant's ability to invest in R&D and strategic initiatives, posing risks to long-term sustainability.
Weak Financial Stability
A declining equity ratio indicates weakening financial stability, which could constrain CollPlant's ability to secure financing and invest in growth opportunities, affecting long-term viability.

Collplant Holdings (CLGN) vs. SPDR S&P 500 ETF (SPY)

Collplant Holdings Business Overview & Revenue Model

Company DescriptionCollplant Holdings (CLGN) is a biotechnology company specializing in regenerative medicine and tissue repair. The company focuses on developing innovative solutions based on its proprietary collagen technology, which is derived from genetically modified tobacco plants. Collplant's core products include a range of collagen-based therapies and medical devices aimed at enhancing wound healing, tissue regeneration, and reconstructive surgery. The company operates primarily in the healthcare sector, targeting applications in orthopedics, aesthetic medicine, and other areas requiring tissue reconstruction and repair.
How the Company Makes MoneyCollplant generates revenue through the commercialization of its collagen-based products and therapies. Its primary revenue streams include sales of medical devices and therapeutic products designed for wound care and tissue regeneration. Additionally, the company may engage in strategic partnerships with other healthcare firms, research institutions, and pharmaceutical companies to co-develop products or license its technology, further enhancing its revenue potential. Collaborations and partnerships may also provide funding through grants or milestone payments, contributing to its overall earnings. The company's focus on developing novel applications of its collagen technology positions it to capitalize on growing market demands in the regenerative medicine field.

Collplant Holdings Earnings Call Summary

Earnings Call Date:Aug 20, 2025
(Q4-2024)
|
% Change Since: |
Next Earnings Date:Nov 26, 2025
Earnings Call Sentiment Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.
Q4-2024 Updates
Positive Updates
Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Regenerative Breast Implant Program Progress
Preclinical testing of commercial-sized breast implants (250cc) shows promising outcomes with depolarization and rapid tissue ingrowth, no complications, and maintained volume retention. This product could revolutionize breast reconstruction and aesthetic enhancements.
AbbVie Collaboration and Financial Milestone
CollPlant received a $2 million payment from AbbVie following development achievements in their dermal filler clinical trials, indicative of continued collaboration and potential future milestones.
Cash Runway Stability
Cash and cash equivalents as of December 31, 2024, were $11.9 million, with an expected operational runway through the second quarter of 2026.
Negative Updates
Significant Revenue Decline
Revenue for the year ended December 31, 2024, was $515,000, a sharp decrease from $11 million in 2023, mainly due to a $10 million milestone payment in 2023 not repeated in 2024.
Increased Net Loss
GAAP net loss for the year ended December 31, 2024, was $16.6 million compared to a net loss of $7 million for the year 2023, highlighting increased financial strain.
Company Guidance
During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.

Collplant Holdings Financial Statement Overview

Summary
Collplant Holdings is facing significant financial challenges, including a drastic revenue decline, negative profit margins, and deteriorating cash flow. Despite low debt levels, the company's shrinking assets and equity indicate financial instability, posing a substantial risk.
Income Statement
35
Negative
Collplant Holdings has experienced significant revenue volatility, with a notable revenue decline from $10.96 million in 2023 to $0.515 million in 2024. The company is struggling with negative margins, including a gross profit margin of -215% and a net profit margin of -3226% in 2024. Despite a brief profitable period in 2021, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.
Balance Sheet
50
Neutral
The company's debt-to-equity ratio remains low at 0.23 in 2024, reflecting a conservative leverage approach. However, stockholders' equity has decreased significantly, and the equity ratio has dropped from 88% in 2021 to 72% in 2024, indicating weakening financial stability. The company's asset base has also shrunk considerably over the same period.
Cash Flow
30
Negative
Collplant Holdings' free cash flow has deteriorated significantly, with a negative free cash flow of $14.58 million in 2024, compared to $3.72 million in 2023. The operating cash flow to net income ratio and free cash flow to net income ratio are both negative, showing a lack of cash flow generation. Despite previous years of positive cash flow from financing activities, the company's cash reserves are depleting.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.40M515.00K10.96M299.00K15.64M6.14M
Gross Profit1.25M-1.11M8.97M-101.00K13.64M3.13M
EBITDA-12.37M-16.21M-6.41M-16.02M838.00K-4.94M
Net Income-13.00M-16.61M-7.02M-16.75M409.00K-5.81M
Balance Sheet
Total Assets17.44M18.71M34.13M37.77M51.22M10.84M
Cash, Cash Equivalents and Short-Term Investments11.71M11.91M26.67M29.65M43.30M3.33M
Total Debt3.03M3.08M3.16M2.91M3.61M3.39M
Total Liabilities4.93M5.25M5.79M5.49M6.10M6.36M
Stockholders Equity12.51M13.46M28.34M32.28M45.12M4.48M
Cash Flow
Free Cash Flow-10.75M-14.58M-3.72M-15.01M912.00K-4.97M
Operating Cash Flow-10.54M-14.09M-2.76M-13.70M2.50M-4.45M
Investing Cash Flow-209.05K-539.00K-1.16M28.92M-31.56M-519.00K
Financing Cash Flow3.12M9.00K1.11M1.87M38.76M4.46M

Collplant Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.28
Price Trends
50DMA
2.53
Negative
100DMA
2.24
Positive
200DMA
2.59
Negative
Market Momentum
MACD
-0.07
Positive
RSI
44.09
Neutral
STOCH
23.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 2.28 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.53, and below the 200-day MA of 2.59, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 44.09 is Neutral, neither overbought nor oversold. The STOCH value of 23.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.

Collplant Holdings Risk Analysis

Collplant Holdings disclosed 81 risk factors in its most recent earnings report. Collplant Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Collplant Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
$26.13M-127.48%-95.87%35.25%
46
Neutral
$27.90M-4.73
44
Neutral
$26.65M-88.27%32.57%
41
Neutral
$32.41M-0.90-312.77%61.18%
40
Underperform
$28.74M-2.02-78.25%248.62%26.22%
30
Underperform
$29.28M31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLGN
Collplant Holdings
2.28
-1.62
-41.54%
DARE
Daré Bioscience
2.11
-1.80
-46.04%
PASG
Passage Bio
7.14
-6.15
-46.28%
PYPD
PolyPid
3.44
0.02
0.58%
SABS
SAB Biotherapeutics
3.03
0.11
3.77%
NRSN
Neurosense Therapeutics Ltd.
1.18
-0.17
-12.59%

Collplant Holdings Corporate Events

CollPlant’s BioInk Outperforms Matrigel in Technion Study
Oct 20, 2025

On October 20, 2025, CollPlant Biotechnologies announced positive results from a study conducted by the Technion – Israel Institute of Technology, which demonstrated that its rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation. This suggests that Collink.3D™ could serve as a next-generation, animal-free extracellular matrix for advanced tissue engineering and research applications, potentially impacting the market for basement membrane matrices, which is projected to grow significantly by 2031.

CollPlant and Mayo Clinic Unveil Humanized 3D Bioprinted Skin Model
Oct 16, 2025

On October 16, 2025, CollPlant Biotechnologies announced the development of a first-of-its-kind fully humanized 3D bioprinted human skin model by Mayo Clinic researchers, utilizing CollPlant’s rhCollagen-based bioink. This model, which serves as an alternative to animal testing, has significant implications for cosmetic and pharmaceutical testing, disease modeling, and drug development, offering a sustainable and ethical solution while advancing regenerative medicine.

CollPlant Biotechnologies Reports Positive Non-Clinical Results for Regenerative Filler
Sep 30, 2025

On September 30, 2025, CollPlant Biotechnologies announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler. This product, which combines hyaluronic acid with a modified form of rhCollagen, is designed to offer both immediate and long-lasting benefits in aesthetic medicine. The successful completion of these studies marks a significant milestone for CollPlant as it prepares to advance the filler into clinical trials, potentially redefining standards in aesthetic treatments by integrating contouring precision, structural support, and tissue regeneration.

CollPlant Expands VergenixSTR Distribution in Europe
Sep 15, 2025

On September 15, 2025, CollPlant Biotechnologies announced the expansion of its European distribution network for its VergenixSTR product by signing a new agreement in Poland. VergenixSTR, a soft tissue repair matrix designed to treat tendinopathy, combines rhCollagen with platelet-rich plasma to promote tendon healing. This expansion is part of CollPlant’s strategy to broaden its global distribution network, enhancing its market presence in Europe and the Asia-Pacific region.

CollPlant Biotechnologies Transfers Listing to Nasdaq Capital Market
Sep 12, 2025

CollPlant Biotechnologies Ltd. announced that it has successfully transferred the listing of its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective September 12, 2025. This move is part of the company’s strategic efforts to optimize its market positioning while maintaining the trading symbol ‘CLGN’. The transfer is expected to have no impact on the trading of its shares, ensuring continuity for investors and stakeholders.

CollPlant Biotechnologies Advances Dermal Filler Program and Reports Q2 2025 Financial Results
Aug 20, 2025

On August 20, 2025, CollPlant Biotechnologies reported its financial results for the second quarter of 2025, highlighting significant advancements in its photocurable dermal filler program and regenerative breast implant technology. The company is preparing for clinical studies of its dermal filler, which has shown promising results in preclinical testing, and is expanding its market presence with new appointments and collaborations. CollPlant also reported a decrease in GAAP revenues for the quarter compared to the previous year, but an increase in revenues for the first half of the year due to a milestone payment from AbbVie. The company’s efforts to expand its product distribution and enhance its market position in the regenerative medicine industry are ongoing, with a focus on non-animal-derived collagen solutions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 22, 2025